To test this, we performed Targeted NGS of MLH1, MSH2, MSH6, EPCAM, and PMS2 genes in a big cohort comprising of 711 patients with hereditary BC, 60 patients with sporadic cancer, and 492 healthy donors from Volga and Central Federal Districts, Russian Federation. This evidence concerns the gene PMS2 and cancer.